A combination of atezolizumab (Tecentriq) and bevacizumab appeared effective and safe in patients with advanced malignant peritoneal mesothelioma, according to results from a small single-arm trial. The combination achieved an objective response rate (ORR) of 40% in patients who had progressed on or were resistant to prior platinum-pemetrexed … [Read more...]
A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion
Background: Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that originates from pleural mesothelial cells. In recent years, with the development of asbestos-related industries and the increase in air pollution, its incidence has been increased. The incidence of pulmonary embolism combined with sarcomatoid MPM is very low and the … [Read more...]
Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: prognostic implications
Background: Malignant peritoneal mesothelioma is the most common primary peritoneal neoplasm. The only universally recognised pathological prognostic factor is histopathological subtype. Prognostic markers based on patient features and clinical stages have been disappointing. Aims: To assess the prognostic role of several clinicopathological … [Read more...]
The association between pleural fluid exposure and survival in pleural mesothelioma
Background: Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may not be a simple bystander of malignancy, but potentially has biological properties improving cancer cell survival and promoting cancer progression. If this is the case, MPE management may need … [Read more...]
Vinorelbine extends PFS in relapsed malignant pleural mesothelioma
Vinorelbine combined with active supportive care conferred superior [ progression-free survival (PFS) ] compared with active supportive care alone among patients with relapsed malignant pleural mesothelioma, according to phase 2 study results. “All patients with malignant pleural mesothelioma eventually relapse following standard … [Read more...]
Health groups sue to make EPA evaluate ‘legacy’ asbestos risk
Health and environmental groups have sued the Environmental Protection Agency [(EPA)], seeking a court order compelling it to evaluate the risks posed by so-called “legacy” asbestos used in old products and buildings. In a complaint filed Tuesday in federal court in San Francisco, groups including the nonprofit Asbestos Disease Awareness … [Read more...]
Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions
Objectives: Medical management based on palliative chemotherapy is currently the standard of care in malignant pleural mesothelioma (MPM). Median survival of 12–16 months has been reported with modern chemotherapy regimens with or without anti-angiogenic agents. Multimodality therapy incorporating cytoreductive surgery, systemic chemotherapy … [Read more...]
Nivolumab prolongs PFS, OS in relapsed malignant mesothelioma
Nivolumab significantly prolonged PFS and OS compared with placebo for patients with [ relapsed mesothelioma ], according to findings presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. “Mesothelioma is predominately a disease that is not suitable for surgery and is one for which chemotherapy has … [Read more...]
Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma
Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of tumor size in only a minority of patients. Predicting response to chemotherapy in patients with MPM by using a genetic marker would, therefore, enable patient … [Read more...]
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Background: Malignant pleural mesothelioma (MPM) has few treatment options. [ Keytruda (pembrolizumab) ] showed preliminary clinical benefit in programmed death ligand 1 (PD-L1)-positive MPM. We evaluated the efficacy and safety of [ Keytruda (pembrolizumab) ] monotherapy in patients with previously treated MPM irrespective of PD-L1 status in … [Read more...]
- 1
- 2
- 3
- …
- 20
- Next Page »